Changchun BCHT Biotechnology Co.

Shanghai Stock Exchange 688276.SS

Changchun BCHT Biotechnology Co. Revenue for the year ending December 31, 2023: USD 255.17 M

Changchun BCHT Biotechnology Co. Revenue is USD 255.17 M for the year ending December 31, 2023, a 64.35% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Changchun BCHT Biotechnology Co. Revenue for the year ending December 31, 2022 was USD 155.26 M, a -17.93% change year over year.
Changchun BCHT Biotechnology Co. Revenue for the year ending December 31, 2021 was USD 189.17 M, a -14.33% change year over year.
Changchun BCHT Biotechnology Co. Revenue for the year ending December 31, 2020 was USD 220.82 M, a 57.61% change year over year.
Changchun BCHT Biotechnology Co. Revenue for the year ending December 31, 2019 was USD 140.11 M, a -5.43% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

Shanghai Stock Exchange: 688276.SS

Changchun BCHT Biotechnology Co.

CEO	Mr. Wei Kong
IPO Date	June 25, 2021
Location	China
Headquarters	1260 Huoju Road
Employees	1,241
Sector	Healthcare
Industries Vaccines Biotechnology Pharmaceuticals

Description

Changchun BCHT Biotechnology Co. Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of human vaccines in China and internationally. Its products include live herpes zoster vaccine; live varicella vaccine; live, nasal, and freeze-dried influenza vaccine; and Rabies vaccine (vero cell) for humans. The company was founded in 2004 and is based in Changchun, China.

Key trends

Past 5 years